Aligos therapeutics presents positive data at apasl 2025

South san francisco, calif., march 26, 2025 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from three oral presentations at the 34th annual meeting of the asian pacific association for the study of the liver (apasl) 2025, being held march 26 - 30, 2025 in beijing, china.
ALGS Ratings Summary
ALGS Quant Ranking